Antibody–drug conjugates (ADC) are targeted therapies that are designed to deliver highly potent cytotoxic agents to specific tumor cells saving normal tissue. They combined a monoclonal antibody (mAbs directed against a specific antigen) to a cytotoxic drug. ADCs are rapidly advancing and have shown promising results in cancer treatment. Prof Pruneri, Full Professor of Pathology at the University of Milan and Chair of the Department of Advanced Diagnostics (Milan National Cancer Institute), will share the state of the art of ADC use in cancer treatment, sharing considerations from a pathologist point of view in terms of the importance of biomarker selection and on-target, off-tumour toxicity (OTOT).

Webinar agenda

This webinar will cover:

• ADC action 
• State of the art in biomarker selection

CML is traditionally regarded as a paradigm of precision medicine, under several points of view:
1) it is the first human malignancy whose molecular pathogenesis was unravelled, well before the advent of omics
2) it is the first human malignancy against which the dream of molecularly targeted therapies came true; 
3) it is the first setting in which the power of molecular testing for response monitoring was demonstrated to play a key role in support to clinical decision making;
4) it has always led the way for the forward-looking application of novel technologies to routine diagnostics. 

This webinar will address the fundamental role of the synergy between the lab and the clinic in ensuring optimal outcomes for CML patients.

Webinar agenda:

• 3.00-3.05: Welcome and introduction of Diaceutics and speakers by Antonio Capece
• 3.05-3.25: Chronic Myeloid Leukemia: the essential role of molecular testing as a guide to diagnosis and treatment – presented by Prof. Simona Soverini
• 3.25-3.35 Q&A

Personalized treatment plans for blood cancers rely on the specialized skills of clinical laboratorians using a variety of analytic methods ranging from microscopic examination to molecular sequencing. This session will use case examples to highlight the importance of fundamental laboratory methods in diagnosis, prognosis, and treatment of blood cancers in pediatric and adult patients. 

Webinar agenda: 

• At the end of this discussion, the participants will be able to:
• Identify key clinical and morphologic features of various myeloid and lymphoid malignancies
• Recognize essential biomarkers for diagnosis and prognostication 
• Design an effective strategy for specimen utilization based on the needs of their laboratory design and patient population

The Molecular Twin is a proof-of-principle platform that combines data from several clinical and molecular analytes from both tumor and host and applies AI and machine learning approaches to identify specific multi-omic biomarker panels which are highly predictive of disease survival outcome. When used in surgically resected pancreatic ductal adenocarcinoma (PDAC), the platform established a model which best predicted survival in patients as well as generated multiple models with significantly better predictive performance than the current PDAC marker of CA 19-9. This event will also cover how these models can both be implemented in resource-poor areas and similarly generated for additional types of cancer.
 
Webinar agenda:

• Review precision medicine in the current landscape of single-omics
• Extend precision medicine to multi-omics
• Discuss how AI and Multi-omics can improve clinical testing and care
• Investigate the future of multi-omics and machine learning

The most common forms of pediatric tumors are acute leukemia (33%), brain tumors (25%), and lymphomas (15%). Diagnosing these tumors utilizes various tests, including those performed by a pathologist (such as IHC) and those that are platform-based (like NGS). The findings from these tests influence treatment options, and pediatric cancers are increasingly treatable pathologies as advanced therapeutics are now available. Bone marrow transplants, immunotherapy, and genetically modified cells that attack tumors are all examples of these therapeutic options. This event will focus on brain and hematological tumors, including identification of biomarkers, discussion of the testing landscape, and review of potential diagnostic hurdles. 

Webinar agenda:

• 3.00-3.05: Diaceutics and speakers introduction
• 3.05-3.25: Brain tumors – Presentation by Dr. Maura Massimino
• 3.25-3.35 Q&A (All participants).
• 3.35-3.55: Hematological tumors – Presentation by Dr. Olga Weinberg
• 3.55-4:05 Q&A and final discussion (All participants).
   

The difficulties in making an accurate diagnosis, the workload in terms of time and the small number of pathologists represent significant problems in laboratory routine. From this perspective, a system based on artificial intelligence could act as a solution or support for the doctor. Digital pathology with the use of high-resolution scanners has allowed the creation of integrated systems that allow tissue characteristics to be observed directly from a computer monitor and manual annotations to be inserted for tumor detection. All this has facilitated the development of automatic algorithms based on neural networks for image classification. Integration of AI tools in routine practice Experience of the department of Pathology of the UHG Paris Saclay, France.

Get insights from leading experts, Dr. Normanno and Prof. Turnbull, as they discuss the implications of large NGS panels, co-mutations, and the introduction of patients harboring germline variants. Discover the significance of germline follow-up and implications. Engage in a dynamic Q&A session to have your questions answered directly by the speakers. Don't miss out on this opportunity to deepen your understanding of precision oncology!

Early detection and management of early-stage cancers are keys for improved quality of life, survival, and to reduce the financial burden of cancer treatments which are much greater at later stage detection. However, many issues exist in routine clinical practice, notably for biomarkers assessment and rapid access to optimal care of the early-stage cancers. We will present the current challenges in early-stage cancer care.

Measurable or minimal residual disease (MRD) is the presence of very small numbers of tumor cells which may remain in the body following treatment. MRD testing currently has multiple clinical uses including the identification of disease relapse or in guiding patient treatment. MRD has traditionally been used in hematological indications but due to the increased availability of next generation sequencing (NGS) circulating tumor DNA (ctDNA) based testing, MRD is increasingly being leveraged in solid tumor indications.

During this webinar, our internal expert on MRD testing, Dr. Bob Holt (Senior Director, Precision Medicine Strategy Advisor) will give an overview of the current and future use of Minimal residual disease (MRD) in hematological and solid tumors. He will analyze the clinical utility, the technology available and barriers that can arise using MRD providing also insights into key factors on the use of MRD in clinical trials.

Following the webinar, Prof. Maria Teresa Voso from Tor Vergata University, Rome will present her daily routine (with pros and cons) of the use of MRD in AML opening a discussion with Bob Holt and all the attendees in the networking lounge. 

Prof Pantel will give an introduction and review to the evolution of precision medicine and will then focus on the implementation of Liquid Biopsy in Precision Oncology.